Daniel S. Chen
CancerInternal medicinePathologyOncologyAntigenAntibodyImmunologyAtezolizumabT cellTumor microenvironmentLung cancerImmunotherapyBevacizumabCancer immunotherapyPD-L1DocetaxelIn patientPhases of clinical researchCancer researchMonoclonal antibodyMedicineBiologyImmune system
Publications 88
#1Elizabeth Budde (City of Hope National Medical Center)H-Index: 6
#2Ajay K. Gopal (Seattle Cancer Care Alliance)H-Index: 3
Last. Philippe Armand (Harvard University)H-Index: 77
view all 14 authors...
1 CitationsSource
#1Paolo A. AsciertoH-Index: 91
#2Bernard A. FoxH-Index: 44
Last. Jeffrey S. Weber (NYU: New York University)H-Index: 1
view all 34 authors...
The hypoxia and profound inflammatory response associated with the pneumonitis observed with the severe acute respiratory virus coronavirus-2 (SARS-COV-2) virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan,
39 CitationsSource
#1Maud Léa Mayoux (Hoffmann-La Roche)H-Index: 2
#2Andreas Roller (Hoffmann-La Roche)H-Index: 19
Last. Wei Xu (Hoffmann-La Roche)H-Index: 2
view all 22 authors...
PD-L1/PD-1 blocking antibodies have demonstrated therapeutic efficacy across a range of human cancers. Extending this benefit to a greater number of patients, however, will require a better understanding of how these therapies instigate anticancer immunity. Although the PD-L1/PD-1 axis is typically associated with T cell function, we demonstrate here that dendritic cells (DCs) are an important target of PD-L1 blocking antibody. PD-L1 binds two receptors, PD-1 and B7.1 (CD80). PD-L1 is expressed ...
61 CitationsSource
#1Priti Hegde (Genentech)H-Index: 31
#2Daniel S. ChenH-Index: 40
Summary Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical fin...
165 CitationsSource
#1Paolo A. AsciertoH-Index: 91
#2Bernard A. FoxH-Index: 44
Last. Jeffrey S. WeberH-Index: 89
view all 34 authors...
1 Citations
#1Omid HamidH-Index: 84
#2Luciana Molinero (Genentech)H-Index: 31
Last. F. Stephen Hodi (Harvard University)H-Index: 126
view all 15 authors...
Purpose: Atezolizumab (anti-programmed death-ligand 1 [PD-L1]) selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity. We evaluated the long-term safety and activity of atezolizumab, along with biological correlates of clinical activity endpoints, in a cohort of patients with melanoma in an ongoing phase Ia study (NCT01375842). Experimental Design: Patients with unresectable or metastatic melanoma were enrol...
19 CitationsSource
#1Rajendra S. Apte (WashU: Washington University in St. Louis)H-Index: 37
#2Daniel S. ChenH-Index: 40
Last. Napoleone Ferrara (UCSD: University of California, San Diego)H-Index: 179
view all 3 authors...
The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our understanding of vasculogenesis and angiogenesis during development and physiological homeostasis. Over a short span of two decades, our understanding of the molecular mechanisms by which VEGF coordinates neurovascular homeostasis has become more sophisticated. The central role of VEGF in the pathogenesis of diverse cancers and blinding eye diseases has also become evident. Elucidation of the molecular regu...
274 CitationsSource
#1Apostolia Maria Tsimberidou (University of Texas MD Anderson Cancer Center)H-Index: 68
#2Laura A. Levit (American Society of Clinical Oncology)H-Index: 14
Last. Michael A. Postow (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 75
view all 10 authors...
PurposeTo develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments.MethodsASCO and the Society for Immunotherapy of Cancer (SITC) convened a working group that consisted of practicing medical oncologists, immunologists, clinical researchers, biostatisticians, and representatives from industry and government to develop Trial Reporting in Immuno-Oncology (TRIO) recommendations. These r...
9 CitationsSource
#1David F. McDermott (Harvard University)H-Index: 93
#2Mahrukh Huseni (Genentech)H-Index: 15
Last. Thomas Powles (QMUL: Queen Mary University of London)H-Index: 84
view all 32 authors...
In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The error has been corrected in the HTML and PDF versions of this article.
10 CitationsSource
#1Marcin Kowanetz (Genentech)H-Index: 41
#2Wei Zou (Genentech)H-Index: 18
Last. Priti Hegde (Genentech)H-Index: 31
view all 30 authors...
Programmed death-ligand 1 (PD-L1) expression on tumor cells (TCs) by immunohistochemistry is rapidly gaining importance as a diagnostic for the selection or stratification of patients with non-small cell lung cancer (NSCLC) most likely to respond to single-agent checkpoint inhibitors. However, at least two distinct patterns of PD-L1 expression have been observed with potential biological and clinical relevance in NSCLC: expression on TC or on tumor-infiltrating immune cells (ICs). We investigate...
82 CitationsSource